Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27238569 | 0.89 | GRIN2D (0.41) | MAPK1KDM1ACTSSCXCR3ALDH1A1 | |
| SCHEMBL24762229 | 0.87 | RORC (0.33) | CTSSCYP2C19EPHX2 | |
| SCHEMBL24763407 | 0.81 | AKR1C3 (0.36) | MAPK1KDM1A | |
| SCHEMBL24763409 | 0.81 | AKR1C3 (0.36) | CYP2C19ALDH1A1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL24763412 | 0.79 | LMNA (0.39) | MAPK1ALDH1A1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL24762716 | 0.75 | RORC (0.34) | CTSS | |
| SCHEMBL24762030 | 0.71 | CA1 (0.35) | CTSSALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL30364193 | 0.69 | SIGMAR1 (0.58) | — | |
| SCHEMBL24762049 | 0.69 | CXCR3 (0.40) | MAPK1EPHX2CXCR3 | |
| SCHEMBL24762050 | 0.68 | LMNA (0.41) | ALDH1A1LMNAKMT2ASMN1; SMN2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190821-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES INC (US) | 2024-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190821-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | PACSIN2, TPX2, PRSS12 | MAPK1 4005/4885KDM1A 4539/4885CTSS 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.